Exploring how creatine affects the development of protective cells in the intestines during colitis.
Official title: Determining the role of the creatine pathway regulation of intestinal goblet cell development in colitis
Funded at University of Colorado Denver · NIH-11166343 · Data updated 2026-11-12
This study is looking at how creatine, a substance your body makes, helps create special cells that keep your intestines healthy, and it's aimed at people with inflammatory bowel disease (IBD) like ulcerative colitis and Crohn's disease, to find new ways to improve gut health.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $163,119 |
| NIH project number | 5K08DK139375-02 |
| Project ID | NIH-11166343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with inflammatory bowel disease, such as ulcerative colitis or Crohn's disease.
✕Less likely to help
Patients without inflammatory bowel disease or those who do not have issues related to intestinal barrier function may not benefit from this research.
What this research studies
This research investigates the role of the creatine pathway in the development of goblet cells, which are crucial for maintaining the protective mucous layer in the intestines. By understanding how creatine influences intestinal cell differentiation, the study aims to address the underlying issues in inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease. The researchers will analyze the effects of creatine deficiency on goblet cell production and mucous layer formation, which are vital for gut health. This could lead to new therapeutic strategies that focus on enhancing the intestinal barrier rather than solely suppressing the immune system.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with inflammatory bowel disease by enhancing the intestinal barrier function.
How similar studies have gone: Previous research has shown promising results in understanding the role of creatine in intestinal health, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Hall, Caroline H — University of Colorado Denver
- Study coordinator: Hall, Caroline H
Related research
Other NIH-funded projects on the same topics.
-
How our genes and immune system affect C. difficile infections
This project looks at how a common human gene variant and immune factors influence the severity of C. difficile infections and whether targeting inflammation could help patients.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
-
Selenium supplementation to help moderate-severe ulcerative colitis flare-ups
This grant tests whether giving selenium can help people with moderate to severe ulcerative colitis reduce flares and improve symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.